ClinicalTrials.gg
CompletedNCT00735696Updated Dec 29, 2014Results posted

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

A Phase 2 interventional study of Ramucirumab and Paclitaxel in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-29.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 24
41 · median 74
Started
2009
the only one that year
Phase 2
14 of 24
1 open now
Registered
1st of 24
by date
Lead sponsor
10 of 24
Eli Lilly and Company

Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is the only one that started in 2009, is one of 14 in phase 2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer

Read the detailed description

Non-small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancers. The advanced stages are associated with poor survival rates, a median survival rate of approximately 3.9 months if left untreated.

Angiogenesis is a process for wound healing and restoring blood flow to tissues after injury. It is the physiological process involving the growth of new blood vessels from pre-existing vessels. Angiogenesis may be promoted by growth factors and in diseases such as cancer, where growth factors are over expressed, the body loses the ability to maintain a balanced angiogenesis. This may embellish the existing supplies of blood; potentially increasing the delivery of oxygen and nutrients supplies for cancer growth and survival.

Ramucirumab is an angiogenesis inhibitor; and is believed to block the promotion of the growth factor to form new blood vessels, thus reducing the blood supply to the cancer cells.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Non Small Cell Lung Cancer
  • Lung
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed NSCLC
  • Advanced NSCLC
  • (as defined by [RECIST 1.0])
  • (ECOG) Performance Status is ≤ 1
  • Age ≥ 18 years
  • Adequate hematologic function = an (ANC) ≥ 1500/μL, ≥ 9 g/dL, and a count ≥ 100,000/microliter (μL)
  • Adequate hepatic function = a total ≤ 1.5 mg/dL transaminases and alkaline phosphatase ≤ 5 x the (ULN)
  • Adequate renal function serum creatinine ≤ 1.5 x ULN or calculated (CrCl) > 60 mL/minute, and urine dipstick for protein \< 1+ (ie, either 0 or trace)
  • Adequate coagulation function, ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above ULN
  • Adequate
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Untreated
  • Prior bevacizumab therapy
  • Radiologically documented evidence of major blood vessel invasion or encasement by cancer
  • Prior systemic chemotherapy for Stage IIIB/IV NSCLC
  • Prior systemic chemotherapy or radiation therapy for Stage I-IIIA NSCLC \< 1 year prior
  • Any concurrent other than basal cell skin cancer, or carcinoma in situ of the cervix
  • Concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy
  • Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Uncontrolled thrombotic or hemorrhagic disorders
  • Poorly-controlled hypertension
  • Chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of function
  • History of gross hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon)
  • Serious non-healing wound, ulcer, or bone fracture
  • Undergone major surgery or subcutaneous venous access device placement. Post-operative bleeding complications or wound complications from a surgical procedures performed in the last 2 months
  • Elective or a planned major surgery to be performed during the course of the trial
  • Peripheral neuropathy ≥ Grade 2 (National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0 [ v 3.0])
  • If female, is pregnant or lactating
  • Radiographic evidence of intratumor cavitation
  • Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    ramucirumab + paclitaxel + carboplatin

    Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle). In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks.

    Biological: Ramucirumab · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • BiologicalRamucirumab

    10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.

    Also known as: IMC-1121B, LY3009806

  • 200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.

  • Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Are Progression-free (PFS) at 6 Months

    Data presented are the percentage of participants without disease progression or death at 6 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progressive disease was defined as having at least a 20% increase in sum of longest diameter of target lesions or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.

    Time frame: 6 months

Secondary outcomes

  1. Summary of Participants Reporting Adverse Events

    Data presented are the number of participants who experienced ramucirumab related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of ramucirumab treatment, and any TEAE leading to dose modification ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.

    Time frame: Baseline up to 32.5 months

  2. Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])

    Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.

    Time frame: First dose to measured progressive disease or death due to any cause up to 32.5 months

  3. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression, initiation of additional antitumor therapy is first reported, or death as a result of any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

    Time frame: First dose up to 32.5 months

  4. Overall Survival (OS) at 1 Year

    Data presented are the percentage of participants surviving at least 12 months after first dose of study medication.

    Time frame: First dose to 1 year

  5. Progression-free Survival (PFS)

    Defined as the time from date of first dose of study medication to the first documented disease progression as defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0), initiation of additional antitumor therapy was first reported or death due to any cause. Participants who did not progress, who discontinued treatment for toxicity or a reason other than documented progression, or who were lost to follow-up before documented progression or death were censored at date of last tumor assessment. Participants who started new therapeutic anticancer treatment prior to documented progression or death were censored at date of last tumor assessment prior to new therapeutic anticancer therapy.

    Time frame: First dose to measured progressive disease or death due to any cause, up to 32.5 months

  6. Overall Survival (OS)

    Overall survival is defined as the time from the first dose of study medication to the date of death from any cause. Participants who were alive at the end of the follow-up period or lost to follow-up were censored on the last date the patient was known to be alive.

    Time frame: First dose to death due to any cause, up to 32.5 months

  7. Serum Anti-Ramucirumab Antibody Assessment

    The number of participants who developed treatment emergent antibody responses to ramucirumab after baseline.

    Time frame: Week 15 (Cycle 5)

  8. Maximum Concentration of Ramucirumab (Cmax)

    Time frame: Week 18 (Cycle 6), at 1-Hour Post End of Infusion

07

Results

Posted Dec 29, 2014

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab + Paclitaxel + Carboplatin
Started41
Received any quantity of study drug40
Completed39
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Enrolled but never treated1

Outcome measures

PrimaryPercentage of Participants Who Are Progression-free (PFS) at 6 Months

Data presented are the percentage of participants without disease progression or death at 6 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progressive disease was defined as having at least a 20% increase in sum of longest diameter of target lesions or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.

Time frame:
6 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Progression-free (PFS) at 6 Months
percentage of participantsRamucirumab + Paclitaxel + Carboplatin
Percentage of Participants Who Are Progression-free (PFS) at 6 Months59.0 (41.3 to 72.9)
SecondarySummary of Participants Reporting Adverse Events

Data presented are the number of participants who experienced ramucirumab related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of ramucirumab treatment, and any TEAE leading to dose modification ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.

Time frame:
Baseline up to 32.5 months
Reported as:
Number · participants
Summary of Participants Reporting Adverse Events
participantsRamucirumab + Paclitaxel + Carboplatin
Any ramucirumab related TEAE34
Any ramucirumab related Serious TEAE8
Any ramucirumab related Grade >= 3 TEAE15
Any TEAE Leading to Discontinuation of ramucirumab13
TEAE Leading to Dose Modification of ramucirumab24
Any ramucirumab related TEAE with Outcome of Death0
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])

Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.

Time frame:
First dose to measured progressive disease or death due to any cause up to 32.5 months
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])
percentage of participantsRamucirumab + Paclitaxel + Carboplatin
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])55.0 (38.5 to 70.7)
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression, initiation of additional antitumor therapy is first reported, or death as a result of any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

Time frame:
First dose up to 32.5 months
Reported as:
Median · months
Duration of Response
monthsRamucirumab + Paclitaxel + Carboplatin
Duration of Response5.54 (4.27 to 8.21)
SecondaryOverall Survival (OS) at 1 Year

Data presented are the percentage of participants surviving at least 12 months after first dose of study medication.

Time frame:
First dose to 1 year
Reported as:
Number · percentage of participants
Overall Survival (OS) at 1 Year
percentage of participantsRamucirumab + Paclitaxel + Carboplatin
Overall Survival (OS) at 1 Year74.6 (57.9 to 85.4)
SecondaryProgression-free Survival (PFS)

Defined as the time from date of first dose of study medication to the first documented disease progression as defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0), initiation of additional antitumor therapy was first reported or death due to any cause. Participants who did not progress, who discontinued treatment for toxicity or a reason other than documented progression, or who were lost to follow-up before documented progression or death were censored at date of last tumor assessment. Participants who started new therapeutic anticancer treatment prior to documented progression or death were censored at date of last tumor assessment prior to new therapeutic anticancer therapy.

Time frame:
First dose to measured progressive disease or death due to any cause, up to 32.5 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsRamucirumab + Paclitaxel + Carboplatin
Progression-free Survival (PFS)7.85 (5.49 to 9.86)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the first dose of study medication to the date of death from any cause. Participants who were alive at the end of the follow-up period or lost to follow-up were censored on the last date the patient was known to be alive.

Time frame:
First dose to death due to any cause, up to 32.5 months
Reported as:
Median · months
Overall Survival (OS)
monthsRamucirumab + Paclitaxel + Carboplatin
Overall Survival (OS)16.85 (14.82 to 28.58)
SecondarySerum Anti-Ramucirumab Antibody Assessment

The number of participants who developed treatment emergent antibody responses to ramucirumab after baseline.

Time frame:
Week 15 (Cycle 5)
Reported as:
Number · participants
Serum Anti-Ramucirumab Antibody Assessment
participantsRamucirumab + Paclitaxel + Carboplatin
Serum Anti-Ramucirumab Antibody Assessment1
SecondaryMaximum Concentration of Ramucirumab (Cmax)
Time frame:
Week 18 (Cycle 6), at 1-Hour Post End of Infusion
Reported as:
Mean · micrograms/milliliter (mcg/mL)
Maximum Concentration of Ramucirumab (Cmax)
micrograms/milliliter (mcg/mL)Ramucirumab + Paclitaxel + Carboplatin
Maximum Concentration of Ramucirumab (Cmax)372 ± 82.9

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab + Paclitaxel + Carboplatin—19/40 (47.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventRamucirumab + Paclitaxel + Carboplatin
FEBRILE NEUTROPENIABlood and lymphatic system disorders4/40
NEUTROPENIABlood and lymphatic system disorders2/40
CATHETER SEPSISInfections and infestations2/40
NAUSEAGastrointestinal disorders1/40
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/40
VOMITINGGastrointestinal disorders1/40
CHILLSGeneral disorders1/40
FATIGUEGeneral disorders1/40
INFUSION RELATED REACTIONGeneral disorders1/40
CHOLECYSTITISHepatobiliary disorders1/40
Most frequent other events
Showing 10 of 88
Most frequent other events
EventRamucirumab + Paclitaxel + Carboplatin
FATIGUEGeneral disorders29/40
NEUROPATHY PERIPHERALNervous system disorders27/40
NAUSEAGastrointestinal disorders23/40
ALOPECIASkin and subcutaneous tissue disorders23/40
CONSTIPATIONGastrointestinal disorders16/40
ARTHRALGIAMusculoskeletal and connective tissue disorders16/40
DIARRHOEAGastrointestinal disorders14/40
VOMITINGGastrointestinal disorders14/40
NEUTROPENIABlood and lymphatic system disorders13/40
THROMBOCYTOPENIABlood and lymphatic system disorders13/40

Baseline characteristics

Modified intent to treat population (mITT): All participants who received any quantity of study drug.

Age, Categorical
Age, Categorical(Participants)Ramucirumab + Paclitaxel + Carboplatin
<=18 years0
Between 18 and 65 years27
>=65 years13
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab + Paclitaxel + Carboplatin
Female25
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab + Paclitaxel + Carboplatin
Hispanic or Latino3
Not Hispanic or Latino37
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ramucirumab + Paclitaxel + Carboplatin
White34
Black or African American4
Asian2
Region of Enrollment
Region of Enrollment(participants)Ramucirumab + Paclitaxel + Carboplatin
United States36
United Kingdom4
08

Study locations

9 sites
  • ImClone Investigational Site
    Beverly Hills, California 90211, United States
  • ImClone Investigational Site
    San Francisco, California 94143, United States
  • ImClone Investigational Site
    Aurora, Colorado 80045, United States
  • ImClone Investigational Site
    Bronx, New York 10467, United States
  • ImClone Investigational Site
    New York, New York 10016, United States
  • ImClone Investigational Site
    San Antonio, Texas 78229, United States
  • ImClone Investigational Site
    Seattle, Washington 98104, United States
  • ImClone Investigational Site
    Cambridge, United Kingdom
  • ImClone Investigational Site
    London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Oct 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 3 years 2 months after primary completion. A results delay was requested in Jul 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2008
First posted
Aug 15, 2008
Start
Jan 2009
Primary completionActual
Oct 2011
CompletionActual
Jan 2012
Results delay requested
Jul 26, 2010
Results first posted
Dec 29, 2014
Last update
Dec 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00735696
Responsible party
Sponsor
First posted
Aug 15, 2008
Start date
Jan 2009
Primary completion
Oct 2011
Completion
Jan 2012
Results posted
Dec 29, 2014
Last update
Dec 29, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion